Related Experiment Video
Updated: Aug 18, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
[The possible limits of thrombolysis: reocclusion and reperfusion damage]
G Ambrosio1, P Golino, M Chiariello
1Cattedra di Cardiologia, II Facoltà di Medicina e Chirurgia, Università degli Studi Federico II, Napoli.
Insights
Early reocclusion and reperfusion injury can limit the benefits of thrombolytic therapy for acute myocardial infarction. Platelet activation and oxygen radicals are key factors, suggesting antiplatelet and antioxidant strategies may improve outcomes.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Thrombolytic therapy is the standard for acute myocardial infarction (AMI).
- Timely reperfusion aims to restore blood flow to ischemic heart muscle.
- However, complications can limit treatment efficacy.
Purpose:
- To investigate mechanisms limiting thrombolytic therapy effectiveness in AMI.
- To explore early reocclusion and reperfusion injury as key challenges.
- To identify potential therapeutic targets for improving outcomes.
Summary:
- Early reocclusion of infarct-related arteries occurs despite anticoagulation, linked to platelet activation.
- Reperfusion injury, involving oxygen radical generation, causes myocardial damage.
- Animal models suggest antiplatelet and antioxidant interventions may mitigate these issues.
Impact:
- Understanding these mechanisms can lead to improved treatment strategies for AMI.
- Developing therapies to prevent reocclusion and reperfusion injury can enhance thrombolysis benefits.
- Further research may expand the positive impact of reperfusion in cardiac patients.
Abstract:
The availability of safe and potent thrombolytic drugs has made reperfusion within the initial few hours the treatment of choice in a vast number of patients with acute myocardial infarction. However, there remain several problems which may substantially reduce the possible beneficial effects of timely reperfusion of ischemic hearts. One important aspect is represented by the possible reocclusion of the infarct-related vessel. Many clinical studies have documented that in a relatively large proportion of patients, the infarct-related vessel may reocclude within few hours after discontinuation of thrombolytic therapy. This phenomenon would obviously hamper the results of thrombolysis in these patients. Investigation on the mechanisms responsible for this early reocclusion represents an area of active research. The results of several large clinical trials have shown that this phenomenon occurs despite full anticoagulation therapy, and it is apparently unrelated to the specific thrombolytic agent employed. On the other hand, experiments performed with animal models which reproduce the setting of a thrombogenic stimulus in the presence of a coronary artery stenosis have indicated that platelet activation plays a key role in the process of intracoronary thrombus formation, suggesting that antiplatelet interventions may be of benefit in this setting. Another potential problem which might partly offset the benefits of thrombolytic therapy is represented by the occurrence of a form of myocardial injury specifically associated with reperfusion. Several experimental studies have now demonstrated that a large amount of toxic oxygen metabolites (oxygen radicals) can be generated at the time of postischemic reperfusion, and that interventions with agents which can inactivate oxygen radicals, or prevent their formation, can significantly improve recovery of contractility and reduce infarct size in reperfused hearts. Although the actual incidence of this phenomenon is still debated, this issue has received considerable attention, because of the possibility of further expanding the benefits of thrombolysis should reperfusion injury be preventable in man.
Related Concept Videos
Clot Retraction and Fibrinolysis
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke ll: Pathophysiology

